In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Arcturus Therapeutics ((ARCT)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...
Arcturus Therapeutics (ARCT) stock falls as Citi downgrades the company following weak mid-stage trial data for its cystic ...
The average one-year price target for Arcturus Therapeutics Holdings (NasdaqGM:ARCT) has been revised to $45.67 / share. This ...
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients ...
Berkeley Police arrested Arcturus Wiggins for an attempted robbery at a Chevron station in 2024 after a year-long investigation.
Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...
Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...
Shares of Arcturus Therapeutics Holdings fell sharply premarket amid fears about patient complications in the wake of a mid-stage trial of a biotech spray treatment for cystic fibrosis that had mixed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback